Earnings ·
Kamada Ltd. reported record-high first-half 2026 revenues of $100.2 million, a 13% year-over-year increase, with…
KMDAKamada Ltd
Kamada Ltd. reported record-high first-half 2026 revenues of $100.2 million, a 13% year-over-year increase, with second-quarter revenues reaching $54.9 million, up 23%. First-half net income rose 18% to $13.4 million ($0.23 per diluted share), while adjusted EBITDA increased 14% to $25.7 million. The company affirmed its full-year guidance of $200–$205 million in revenues and $50–$53 million in adjusted EBITDA. Kamada also secured a three-year, approximately $50 million strategic agreement to supply plasma to a leading biopharmaceutical company. Additionally, the filing announced that Chief Financial Officer Chaime Orlev will transition out of his role effective December 31, 2026, after nine years of service. Kamada Ltd. is a global biopharmaceutical company specializing in specialty plasma-derived therapies for rare and serious conditions.